Viatris Inc (OQ:VTRS)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 1000 Mylan Boulevard
CANONSBURG PA 15317
Tel: N/A
Website: https://www.viatris.com/en
IR: See website
<
Key People
Scott A. Smith
Chief Executive Officer, Director 		Theodora Mistras
Chief Financial Officer 		Andrew Cuneo
President, Japan, Australia and New Zealand
Xiangyang Ni
President, Greater China 		Paul B. Campbell
Chief Accounting Officer, Corporate Controller 		Brian Roman
Global General Counsel
Business Overview
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as the Company's ARV franchise. Its portfolio comprises more than 1,400 approved molecules across a range of key therapeutic areas, including key brands and generics, including complex products. It operates around 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.
Financial Overview
For the fiscal year ended 31 December 2023, Viatris Inc revenues decreased 5% to $15.43B. Net income decreased 97% to $54.7M. Revenues reflect Developed markets segment decrease of 5% to $9.25B, JANZ segment decrease of 13% to $1.42B, Emerging Markets segment decrease of 2% to $2.55B, United States segment decrease of 10% to $3.55B, China (Country) segment decrease of 3% to $1.89B.
Employees: 38,000 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $30,405M as of Dec 31, 2023
Annual revenue (TTM): $15,427M as of Dec 31, 2023
EBITDA (TTM): $4,341M as of Dec 31, 2023
Net annual income (TTM): $54.70M as of Dec 31, 2023
Free cash flow (TTM): $1,750M as of Dec 31, 2023
Net Debt Last Fiscal Year: $17,045M as of Dec 31, 2023
Shares outstanding: 1,187,569,149 as of Feb 22, 2024
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More